Chongqing Chen'an Biopharmaceutical

Chongqing Chen'an Biopharmaceutical is a Chinese biotechnology company specializing in the development and manufacturing of recombinant protein drugs for metabolic diseases, particularly diabetes and obesity. The company's portfolio features a comprehensive range of insulin analogues, including insulin glargine, insulin aspart, and insulin degludec, alongside GLP-1 receptor agonists such as liraglutide and semaglutide. In early 2024, the company was acquired by Chongqing Zhifei Biological Products, a major player in the Chinese vaccine industry, to serve as its core platform for metabolic disease therapies. Chen'an Biopharmaceutical operates a large-scale, GMP-compliant manufacturing base in Chongqing. Several of its lead products are currently in late-stage clinical trials or under regulatory review in China.